Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04260217
Title APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenstrom Macroglobulinemia (MAPLE-1)
Acronym MAPLE-1
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ascentage Pharma Group Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | AUS

Facility Status City State Zip Country Details
City of Hope RECRUITING Duarte California 91010 United States Details
Colorado Blood Cancer Institute RECRUITING Denver Colorado 80218 United States Details
Mayo Clinic RECRUITING Jacksonville Florida 32224 United States Details
Weill Cornell Univ Hospitals NOT_YET_RECRUITING New York New York 10065 United States Details
MD Anderson RECRUITING Houston Texas 77030 United States Details
St. Vincent Hospital NOT_YET_RECRUITING Melbourne 3065 Australia Details
Nanfang Hospital RECRUITING Guangzhou Guangdong China Details
Zhongshan Hospital of Fudan University RECRUITING Shanghai Shanghai China Details
Beijing Chaoyang Hospital RECRUITING Beijing China Details
The First Affiliated Hospital,College Of Medicine,Zhejiang University RECRUITING Hangzhou China Details
The First Affiliated Hospital with Nanjing Medical University RECRUITING Nanjing China Details
The First Affiliated Hospital Of Soochow University RECRUITING Suzhou China Details
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences RECRUITING Tianjin China Details
Henan Cancer Hospital RECRUITING Zhengzhou China Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field